Julien Grynblat

Julien Grynblat

Auto-generated profile, based on publicly available information

Julien Grynblat

INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Marie Lannelongue Hospital and Bicêtre Hospital, Le Plessis-Robinson, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
JGJulien Grynblat
Julien Grynblat
HBHarm-Jan Bogaard
Harm-Jan Bogaard
MEMélanie Eyries
Mélanie Eyries
OMOlivier Meyrignac
Olivier Meyrignac
LSLaurent SAVALE
Laurent SAVALE
FIFrench PH Network PULMOTENSION investigators
French PH Network PULMOTENSION investigators
Background: Bone morphogenetic proteins 9 and 10 (BMP9 and BMP10), encoded byGDF2andBMP10, respectively, play a pivotal role in pulmonary vascular regulation.GDF2variants have been reported in pulmonary arterial hypertension (PAH) and hereditary haemorrhagic telangiectasia (HHT). However, the phenotype ofGDF2andBMP10carriers remains largely unexplored.Methods: We report the characteristics and outcomes of PAH patients inGDF2andBMP10carriers from the French and Dutch pulmonary hypertension registries. A literature review explored the phenotypic spectrum of these patients.Results: 26 PAH patients were identified: 20 harbouring heterozygousGDF2variants, one homozygousGDF2variant, four heterozygousBMP10variants, and one with bothGDF2andBMP10variants. The prevalence ofGDF2andBMP10variants was 1.3% and 0.4%, respectively. Median age at PAH diagnosis was 30 years, with a female/male ratio of 1.9. Congenital heart disease (CHD) was present in 15.4% of the patients. At diagnosis, most of the patients (61.5%) were in New York Heart Association Functional Class III or IV with severe haemodynamic compromise (median (range) pulmonary vascular resistance 9.0 (3.3–40.6) WU). Haemoptysis was reported in four patients; none met the HHT criteria. Two patients carryingBMP10variants underwent lung transplantation, revealing typical PAH histopathology. The literature analysis showed that 7.6% ofGDF2carriers developed isolated HHT, and identified cardiomyopathy and developmental disorders inBMP10carriers.Conclusions: GDF2andBMP10pathogenic variants are rare among PAH patients, and occasionally associated with CHD. HHT cases amongGDF2carriers are limited according to the literature.BMP10full phenotypic ramifications warrant further investigation.

4 April 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JGJulien Grynblat
Julien Grynblat
MSMalekzadeh-Milani Sophie
Malekzadeh-Milani Sophie
MMMathilde Meot
Mathilde Meot
FPFrederic Perros
Frederic Perros
ISIsabelle Szezepanski
Isabelle Szezepanski
Damien BonnetDamien Bonnet
Damien Bonnet
Background: Right heart catheterization (RHC) is a high‐risk procedure in children with pulmonary arterial hypertension without clear guidelines for the indications and targets of invasive reassessment. Our objectives are to define the aims of repeated RHC and evaluate the correlation between noninvasive criteria and hemodynamic parameters. Methods and Results: Clinical and hemodynamic characteristics from 71 incident treatment‐naïve children (median age 6.2 years) with pulmonary arterial hypertension who had a baseline and reevaluation RHC were analyzed. Correlations between noninvasive predictors and hemodynamic parameters were tested. Adverse outcomes were defined as death, lung transplantation, or Potts shunt. At baseline, pulmonary vascular resistance index (hazard ratio [HR] 1.07 per 1 WU·m 2 increase [95% CI, 1.02–1.12], P =0.002), stroke volume index (HR 0.95 per 1 L·min −1 ·m −2 increase [95% CI, 0.91–0.99], P =0.012), pulmonary artery compliance index (HR 0.16 per 1 mL·mm Hg −1· m −2 increase [95% CI, 0.051–0.52], P =0.002), and right atrial pressure (HR, 1.31 per 1 mm Hg increase [95% CI, 1.01–1.71], P =0.043) were associated with adverse outcomes. Pulmonary vascular resistance index, pulmonary artery compliance index, and right atrial pressure were still associated with a worse outcome at second RHC. Noninvasive criteria accurately predicted hemodynamic evolution; however, 70% of the patients who had improved based on noninvasive criteria still presented at least 1 “at risk” hemodynamics at second RHC. Conclusions: Pulmonary vascular resistance index, pulmonary artery compliance index, and right atrial pressure are solid predictors of adverse outcomes in pediatric pulmonary arterial hypertension and potential therapeutic targets. Noninvasive criteria accurately predict the evolution of hemodynamic parameters, but insufficiently. Repeated RHC are helpful to identify children with persistent higher risk after treatment introduction.

2 May 2024 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
JGJulien Grynblat
Julien Grynblat
CKCharles Khouri
Charles Khouri
AHAlex Hlavaty
Alex Hlavaty
XJXavier Jaïs
Xavier Jaïs
LSLaurent SAVALE
Laurent SAVALE
David MontaniDavid Montani
David Montani
Background: Pulmonary arterial hypertension (PAH) has been described in patients treated with proteasome inhibitors (PIs). Our objective was to evaluate the association between PIs and PAH.Methods: Characteristics of incident PAH cases previously treated with carfilzomib or bortezomib were analysed from the French pulmonary hypertension registry and the VIGIAPATH programme from 2004 to 2023, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization (WHO) global database (VigiBase) and a meta-analysis of randomised controlled trials.Results: 11 incident cases of PI-associated PAH were identified (six with carfilzomib and five with bortezomib) with a female:male ratio of 2.7:1, a median age of 61 years, and a median delay between PI first exposure and PAH of 6 months. Four patients died (two from right heart failure, one from respiratory distress and one from an unknown cause). At diagnosis, six were in New York Heart Association Functional Class III/IV with severe haemodynamic impairment (median mean pulmonary arterial pressure 39 mmHg, cardiac index 2.45 L·min−1·m−2and pulmonary vascular resistance 7.2 WU). In the WHO pharmacovigilance database, 169 cases of PH associated with PI were reported since 2013 with significant signals of disproportionate reporting (SDR) for carfilzomib, regardless of the definition of cases or control group. However, SDR for bortezomib were inconsistent. The systematic review identified 17 clinical trials, and carfilzomib was associated with a significantly higher risk of dyspnoea, severe dyspnoea and PH compared with bortezomib.Conclusion: PIs may induce PAH in patients undergoing treatment, with carfilzomib emitting a stronger signal than bortezomib, and these patients should be monitored closely.

3 August 2023 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
SSSabina Solinas
Sabina Solinas
ABAthénaïs Boucly
Athénaïs Boucly
ABAntoine Beurnier
Antoine Beurnier
MKMithum Kularatne
Mithum Kularatne
JGJulien Grynblat
Julien Grynblat
David MontaniDavid Montani
David Montani
Pulmonary veno-occlusive disease (PVOD) is an orphan disease and uncommon etiology of pulmonary arterial hypertension (PAH) characterized by substantial small pulmonary vein and capillary involvement. PVOD, also known as 'PAH with features of venous/capillary involvement' in the current ESC/ERS classification. In recent years, particular risk factors for PVOD have been recognized, including genetic susceptibilities and environmental factors (such as exposure to occupational organic solvents, chemotherapy, and potentially tobacco). The discovery of biallelic mutations in the EIF2AK4 gene as the cause of heritable PVOD has been a breakthrough in understanding the molecular basis of PVOD. Venous and capillary involvement (PVOD-like) has also been reported to be relatively common in connective tissue disease-associated PAH (especially systemic sclerosis), and in rare pulmonary diseases like sarcoidosis and pulmonary Langerhans cell granulomatosis. Although PVOD and pulmonary arterial hypertension (PAH) exhibit similarities, including severe precapillary PH, it is essential to differentiate between them since PVOD has a worse prognosis and requires specific management. Indeed, PVOD patients are characterized by poor response to PAH-approved drugs, which can lead to pulmonary edema and clinical deterioration. Due to the lack of effective treatments, early referral to a lung transplantation center is crucial.

19 November 2024 in Chest
Verified
Journal Article
Open access
CPCamille Poisson
Camille Poisson
AHAlex Hlavaty
Alex Hlavaty
NFNicolas Favrolt
Nicolas Favrolt
MCMarie-Camille Chaumais
Marie-Camille Chaumais
JGJulien Grynblat
Julien Grynblat
David MontaniDavid Montani
David Montani
Trastuzumab-emtansine have been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH). Is there an association between trastuzumab, trastuzumab-emtansine, or trastuzumab-deruxtecan and the development of PAH? Characteristics of incident PAH cases treated with trastuzumab, trastuzumab-emtansine or trastuzumab-deruxtecan, were analyzed from the French PH Registry, the VIGIAPATH program, concurrently with a pharmacovigilance disproportionality analysis using the WHO pharmacovigilance database using a broad definition of PH and a narrow definition of PAH. A signal of disproportionate reporting was deemed significant if the lower boundary of the 95% credibility interval (95%CI) of the Information Component (IC) was superior to 0. The variables were expressed as median (interquartile range). In the French PH Registry, we identified 8 incident cases of PAH after trastuzumab-emtansine exposure and none with trastuzumab alone or trastuzumab-deruxtecan. All cases occured in women (age of 56 (49-61) years) suffering from breast cancer. The delay between first exposure and PAH diagnosis was 43 (4.5-55) months. At diagnosis, 5 were in NYHA functional class III/IV with severe hemodynamic impairment (mean pulmonary artery pressure of 42 mmHg, cardiac index 2.51 L/min/m2, and pulmonary vascular resistance of 9.7 WU). Disproportionality analysis showed that only trastuzumab-emtansine demonstrated a significant signal of disproportionate reporting using both broad definition of PH (IC 1.46, 0.86-1.95) and narrow definition of PAH (IC 1.76, 0.83-2.46). Trastuzumab displayed a significant signal using only the broad definition of PH, while trastuzumab-deruxtecan was not associated with any significant signals of disproportionate reporting. Our results suggest that more patients exposed to trastuzumab-emtansine developed PH compared to trastuzumab alone. Further assessment of this safety signal and exploration of pathophysiological mechanisms is needed.

11 July 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ETEszter N. Tóth
Eszter N. Tóth
LCLucas R. Celant
Lucas R. Celant
MNMarili Niglas
Marili Niglas
SJSamara Jansen
Samara Jansen
JTJelco Tramper
Jelco Tramper
HBHarm-Jan Bogaard
Harm-Jan Bogaard
Introduction: Pathogenic variants in the gene encoding forBMPR2are a major genetic risk factor for heritable pulmonary arterial hypertension. Owing to incomplete penetrance, deep phenotyping of unaffected carriers of a pathogenicBMPR2variant through multimodality screening may aid in early diagnosis and identify susceptibility traits for future development of pulmonary arterial hypertension.Methods: 28 unaffected carriers (44±16 years, 57% female) and 21 healthy controls (44±18 years, 48% female) underwent annual screening, including cardiac magnetic resonance imaging, transthoracic echocardiography, cardiopulmonary exercise testing and right heart catheterisation. Right ventricular pressure–volume loops were constructed to assess load-independent contractility and compared with a healthy control group. A transgenicBmpr2Δ71Ex1/+rat model was employed to validate findings from humans.Results: Unaffected carriers had lower indexed right ventricular end-diastolic (79.5±17.6 mL·m−2versus62.7±15.3 mL·m−2; p=0.001), end-systolic (34.2±10.5 mL·m−2versus27.1±8.3 mL·m−2; p=0.014) and left ventricular end-diastolic (68.9±14.1 mL·m−2versus58.5±10.7 mL·m−2; p=0.007) volumes than control subjects.Bmpr2Δ71Ex1/+rats were also observed to have smaller cardiac volumes than wild-type rats. Pressure–volume loop analysis showed that unaffected carriers had significantly higher afterload (arterial elastance 0.15±0.06 versus0.27±0.08 mmHg·mL−1; p<0.001) and end-systolic elastance (0.28±0.07 versus0.35±0.10 mmHg·mL−1; p=0.047) in addition to lower right ventricular pulmonary artery coupling (end-systolic elastance/arterial elastance 2.24±1.03versus1.36±0.37; p=0.006). During the 4-year follow-up period, two unaffected carriers developed pulmonary arterial hypertension, with normal N-terminal pro-brain natriuretic peptide and transthoracic echocardiography indices at diagnosis.Conclusion: UnaffectedBMPR2mutation carriers have an altered cardiac phenotype mimicked inBmpr2Δ71Ex1/+transgenic rats. Future efforts to establish an effective screening protocol for individuals at risk for developing pulmonary arterial hypertension warrant longer follow-up periods.